E2 ModeratePreliminaryPEM unclearObservationalPeer-reviewedMachine draft
The influence of age on transfer factor treatment of cellular immunodeficiency, chronic fatigue syndrome and/or chronic viral infections.
Hana, I, Vrubel, J, Pekarek, J et al. · Biotherapy (Dordrecht, Netherlands) · 1996 · DOI
Quick Summary
This study looked at 222 patients with weak immune systems, many of whom also had ME/CFS and/or chronic viral infections (EBV or CMV). They were treated with transfer factor, a type of immune-boosting therapy, given as injections over 8 weeks. The researchers found that younger patients improved more often than older patients, with failure rates rising significantly in those over 54 years old.
Why It Matters
This study suggests that age significantly affects immune system response to transfer factor treatment in ME/CFS patients with cellular immunodeficiency, potentially explaining variable treatment outcomes across age groups. Understanding age-related treatment response is crucial for personalizing therapeutic approaches and setting realistic expectations for patients with ME/CFS and associated immune dysfunction.
Observed Findings
- Clinical improvement failure rates increased with age: 10.6% (ages 17–43), 11.5% (ages 44–53), and 28.9% (ages 54–77)
- Failure to normalize low T-cell counts showed marked age-dependent increase: 10.6%, 21.2%, and 59.6% across age groups
- Persistent absolute lymphocyte counts below 1,200 cells were found in 23.1%, 54.5%, and 89.3% of non-responsive patients in the respective age groups
- Statistical analysis confirmed significant differences among age groups (Pearson Chi-square and linear trend testing)
- Sex and other tested factors did not significantly influence treatment outcomes
Inferred Conclusions
- Age substantially influences the failure rate of cellular immunodeficiency treatment using transfer factor
- Older patients show greater difficulty normalizing T-cell counts, though clinical improvement may still occur
- Diminished baseline lymphocyte numbers in older patients may partially explain reduced treatment efficacy for immune parameters in this age group
Remaining Questions
- Does transfer factor produce genuine immunological improvement beyond placebo effects, and how can this be definitively established in future controlled trials?
- What is the long-term durability of any clinical or immunological improvements observed with transfer factor treatment?
What This Study Does Not Prove
This study does not establish that transfer factor is effective for ME/CFS—it lacks a control group or placebo comparison, and the authors acknowledge a placebo effect cannot be excluded. The observational design cannot prove causation, and findings are limited to this particular preparation (Immodin) and may not generalize to other transfer factor products or patient populations. Age-related differences in treatment response do not establish the underlying biological mechanism.
Tags
Symptom:Fatigue
Biomarker:Blood Biomarker
Method Flag:Weak Case DefinitionNo ControlsSmall SampleExploratory OnlyMixed Cohort
Metadata
- DOI
- 10.1007/BF02628664
- PMID
- 8993765
- Review status
- Machine draft
- Evidence level
- Single-study or moderate support from human research
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →